Clinical trial
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
NCT00678886 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 29, 2008
- Completion date
- January 31, 2012
- Enrollment
- 272 (actual)
- Sites
- 109
Conditions
As the registry lists them; a condition with its own page is linked.